Eli Lilly and Co. (LLY), the company behind weight loss drug Mounjaro, just crossed into some pretty exclusive territory. Its quality score hit 90.04 this week, vaulting it into the top decile of stocks when it comes to fundamental strength. Translation: only about 10% of companies score higher on operational efficiency and financial health.
The timing is interesting because Bank of America just put out a note arguing that investors are still underestimating how dominant Eli Lilly will be in the obesity market. Not just with injectables like Zepbound, but with what's coming next.
Breaking Into the Elite Tier
Eli Lilly's quality score climbed from 89.66 to 90.04 in the latest weekly update. That might sound like a small bump, but it matters because it pushes the stock into what you might call the "elite" category, outranking 90% of its peers on measures like profitability and fundamental indicators.
The quality metric evaluates a company's operational efficiency and financial health by digging into historical profitability patterns. For Eli Lilly, this improvement pairs nicely with an already stellar growth score of 99.38. Finding rapid expansion combined with operational stability isn't exactly common. It's the financial equivalent of being both fast and coordinated.
Wall Street Is Missing the Oral Drug Story
Bank of America analyst Jason Gerberry thinks the market hasn't fully grasped where Eli Lilly's value really lies. Sure, the company dominates injectable GLP-1s like Zepbound, but Gerberry says investors are "under-calling" what happens in the next phase.
He maintains a Buy rating and sees "room for stock upside" as Lilly executes on obesity launches and reduces risk across "nearly every conceivable market segment."
The big prize? Orforglipron, Eli Lilly's oral weight-loss pill set to launch in 2026. Wall Street consensus puts revenue around $1 billion. Bank of America? They're forecasting $3 billion. That's not a rounding error—that's a fundamental disagreement about demand. BofA's thesis hinges on ease of use and global scalability. Pills are just simpler than injections, and that matters when you're trying to reach patients worldwide.
Clinical Data Backs Up the Optimism
On Thursday, Eli Lilly dropped some Phase 3 data that helps explain why its quality score keeps climbing. The ATTAIN-MAINTAIN trial showed that Orforglipron successfully helped patients maintain weight loss after they switched from injectable treatments like Wegovy and Zepbound.
This is huge for de-risking future revenue. If patients can start with an injectable, then transition to a maintenance pill, Lilly has a more flexible treatment pathway. That optionality strengthens the commercial case and reduces the chance that competitors can easily poach patients.
In other words, the clinical wins are translating into financial stability, which is exactly what quality scores are designed to capture.
Stock Performance
LLY stock was up 0.10% in premarket trading on Friday after closing 1.45% higher at $1,056.88 on Thursday. The stock has gained 35.83% year-to-date and 38.57% over the past six months, reflecting growing confidence in its obesity franchise and broader pipeline execution.
